Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, reported positive top-line results from the phase IIb SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the company’s first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.
Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.
